Compare · CLGN vs STE
CLGN vs STE
Side-by-side comparison of CollPlant Biotechnologies Ltd (CLGN) and STERIS plc (Ireland) (STE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CLGN and STE operate in Industrial Specialties (Health Care), so they compete in similar markets.
- STE is the larger of the two at $23.05B, about 4204.1x CLGN ($5.5M).
- Over the past year, CLGN is down 87.7% and STE is down 4.9% - STE leads by 82.8 points.
- STE has been more active in the news (16 items in the past 4 weeks vs 2 for CLGN).
- STE has more recent analyst coverage (17 ratings vs 1 for CLGN).
- Company
- CollPlant Biotechnologies Ltd
- STERIS plc (Ireland)
- Price
- $0.30-1.70%
- $236.43-0.47%
- Market cap
- $5.5M
- $23.05B
- 1M return
- -4.37%
- +8.14%
- 1Y return
- -87.71%
- -4.93%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 2
- 16
- Recent ratings
- 1
- 17
CollPlant Biotechnologies Ltd
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler for treating wrinkles; 3D Bioprinted breast implants that are used for the regeneration of breast tissue; injectable implants to promote breast tissue regeneration; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds. It has a co-development agreement with 3D Systems Corporation for a 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures in combination with an implant. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.
STERIS plc (Ireland)
STERIS plc provides infection prevention and other procedural products and services worldwide. It operates in three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. The Healthcare segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. This segment offers its products and services to acute care hospitals and other healthcare settings. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The Life Sciences segment designs, manufactures and sells consumable products, such as formulated cleaning chemistries, barrier and sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. The company is based in Dublin, Ireland.
Latest CLGN
- SEC Form 6-K filed by CollPlant Biotechnologies Ltd
- SEC Form 6-K filed by CollPlant Biotechnologies Ltd
- SEC Form 6-K filed by CollPlant Biotechnologies Ltd
- SEC Form 6-K filed by CollPlant Biotechnologies Ltd
- SEC Form D filed by CollPlant Biotechnologies Ltd
- SEC Form 424B3 filed by CollPlant Biotechnologies Ltd
- SEC Form EFFECT filed by CollPlant Biotechnologies Ltd
- SEC Form F-3 filed by CollPlant Biotechnologies Ltd
- SEC Form 6-K filed by CollPlant Biotechnologies Ltd
- SEC Form 6-K filed by CollPlant Biotechnologies Ltd
Latest STE
- SEC Form 144 filed by STERIS plc (Ireland)
- SEC Form 4 filed by Director Shapiro Louis
- Director Sohi Mohsen exercised 4,058 units of Ordinary Shares at a strike of $86.23 and sold $956,795 worth of Ordinary Shares (4,058 units at $235.78) (SEC Form 4)
- SEC Form 4 filed by Director Shah Nirav R
- SEC Form 4 filed by Director Martin Paul Edward
- SEC Form 4 filed by Director Boulud Pierre
- SEC Form 4 filed by Director Feldmann Cynthia L
- SEC Form 4 filed by Director Holland Christopher S
- SEC Form 4 filed by Director Alegria Esther M.
- SEC Form 144 filed by STERIS plc (Ireland)